Guidance for ACADIA Pharmaceuticals (ACAD)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | N/A | N/A | $1.22B – 1.28B | $1.20B | = Maintained | Details |
| 2025 | N/A | N/A | $1.07B – 1.10B | $1.07B | = Maintained | Details |
| 2025 | N/A | N/A | $1.03B – 1.09B | $1.06B | = Maintained | Details |
| 2025 | N/A | N/A | $1.03B – 1.09B | $1.05B | = Maintained | Details |
| 2024 | N/A | N/A | $940.00M – 960.00M | $952.50M | = Maintained | Details |
| 2024 | N/A | N/A | $930.00M – 980.00M | $954.20M | = Maintained | Details |
| 2023 | N/A | N/A | $530.00M – 545.00M | $652.10M | = Maintained | Details |
| 2023 | N/A | N/A | $520.00M – 530.00M | $569.00M | = Maintained | Details |
| 2022 | N/A | N/A | $510.00M – 540.00M | $531.00M | = Maintained | Details |
| 2022 | N/A | N/A | $510.00M – 560.00M | $540.70M | = Maintained | Details |
| Q3 2021 | N/A | N/A | $480.00M – 515.00M | $527.70M | = Maintained | Details |
| 2020 | N/A | N/A | $440.00M – 470.00M | N/A | = Maintained | Details |
| 2019 | N/A | N/A | $320.00M – 330.00M | $292.80M |  Raised |
Details |
| 2019 | N/A | N/A | $280.00M – 300.00M | $291.20M | = Maintained | Details |
| 2019 | N/A | N/A | $275.00M – 300.00M | $297.15M | = Maintained | Details |
| Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| 2017 | N/A | N/A | $124.00M – 127.00M | N/A | = Maintained | Details |
| 2017 | N/A | N/A | $105.00M – 115.00M | N/A | = Maintained | Details |
| Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
